Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Classic tumor therapy, consisting of cytotoxic agents and/or targeted therapy, has not overcome therapeutic limitations like poor risk genetic parameters, genetic heterogeneity at different metastatic sites or the problem of undruggable targets. Here we summarize data and trials principally followin...
Saved in:
Main Authors: | Daniel Heudobler (Author), Michael Rechenmacher (Author), Florian Lüke (Author), Martin Vogelhuber (Author), Sebastian Klobuch (Author), Simone Thomas (Author), Tobias Pukrop (Author), Christina Hackl (Author), Wolfgang Herr (Author), Lina Ghibelli (Author), Christopher Gerner (Author), Albrecht Reichle (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis
by: Daniel Heudobler, et al.
Published: (2021) -
A Computational Model of Tumor Growth and Anakoinosis
by: Pan Pantziarka, et al.
Published: (2019) -
Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
by: Daniel Heudobler, et al.
Published: (2018) -
Continuous Complete Remission in Two Patients with Acute Lymphoblastic Leukemia and Severe Fungal Infection Following Short-Term, Dose-Reduced Chemotherapy
by: Florian Lüke, et al.
Published: (2021) -
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)
by: Daniel Heudobler, et al.
Published: (2021)